JP2024523363A - Ifnar1の発現を低減するための化合物及び方法 - Google Patents
Ifnar1の発現を低減するための化合物及び方法 Download PDFInfo
- Publication number
- JP2024523363A JP2024523363A JP2023577658A JP2023577658A JP2024523363A JP 2024523363 A JP2024523363 A JP 2024523363A JP 2023577658 A JP2023577658 A JP 2023577658A JP 2023577658 A JP2023577658 A JP 2023577658A JP 2024523363 A JP2024523363 A JP 2024523363A
- Authority
- JP
- Japan
- Prior art keywords
- modified
- modified oligonucleotide
- oligomeric
- oligomeric compound
- sugar moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163212476P | 2021-06-18 | 2021-06-18 | |
| US63/212,476 | 2021-06-18 | ||
| PCT/US2022/033936 WO2022266415A1 (en) | 2021-06-18 | 2022-06-17 | Compounds and methods for reducing ifnar1 expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024523363A true JP2024523363A (ja) | 2024-06-28 |
| JP2024523363A5 JP2024523363A5 (cg-RX-API-DMAC7.html) | 2025-06-25 |
Family
ID=84527458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023577658A Pending JP2024523363A (ja) | 2021-06-18 | 2022-06-17 | Ifnar1の発現を低減するための化合物及び方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20250188476A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4355338A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024523363A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022266415A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11753644B2 (en) | 2021-06-18 | 2023-09-12 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing IFNAR1 expression |
| TW202442242A (zh) * | 2023-04-21 | 2024-11-01 | 德商瑟卡爾納製藥有限兩合公司 | Nrp1-特異性反義寡核苷酸及其等在預防及/或治療疾病的用途 |
| EP4724582A1 (en) * | 2023-06-07 | 2026-04-15 | Massachusetts Institute of Technology | Rna-loaded lipid nanoparticles |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040241651A1 (en) * | 2000-04-07 | 2004-12-02 | Alexander Olek | Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations |
| US20070093437A1 (en) * | 2001-05-18 | 2007-04-26 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of xiap gene expression using short interfering nucleic acid (sina) |
| JP2010537629A (ja) * | 2007-08-30 | 2010-12-09 | アカデミシュ ジーケンハウス ビイ デ ユニヴェアズィテート ファン アムステルダム | 動脈形成に関与する経路及びその使用 |
| WO2012068630A1 (en) * | 2010-11-26 | 2012-05-31 | The University Of Melbourne | Methods and compositions comprising antagonists of type 1 interferon-mediated signalling for reducing a neuroinflammatory response in the central nervous system following a stroke |
| CN104312973A (zh) * | 2014-10-09 | 2015-01-28 | 北京师范大学 | I型干扰素在诱导atx蛋白表达中的应用 |
| JP2015513912A (ja) * | 2012-04-02 | 2015-05-18 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | タンパク質の産生のための修飾ポリヌクレオチド |
| WO2016009430A1 (en) * | 2014-07-14 | 2016-01-21 | Yeda Research And Development Co. Ltd | Reduction of aging-induced type i interferon signaling at the brain's choroid plexus or within the cns for treatment of disease or injury of the cns |
| JP2018511307A (ja) * | 2015-04-03 | 2018-04-26 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | Tmprss6発現を調節するための化合物及び方法 |
| JP2019506438A (ja) * | 2016-02-24 | 2019-03-07 | チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド | がんの処置のためのsmc組合せ療法 |
| JP2020517296A (ja) * | 2017-04-28 | 2020-06-18 | アベリノ ラボ ユーエスエー インコーポレイテッドAvellino Lab USA, Inc. | 円錐角膜に関連する対立遺伝子を検出する方法 |
| WO2020205463A1 (en) * | 2019-03-29 | 2020-10-08 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating ube3a-ats |
| WO2021087164A1 (en) * | 2019-10-30 | 2021-05-06 | Shire Human Genetic Therapies, Inc. | Methods for detecting oligonucleotides |
| JP2021512629A (ja) * | 2018-02-12 | 2021-05-20 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | 修飾化合物及びその使用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0807172A1 (en) * | 1995-01-30 | 1997-11-19 | HYBRIDON, Inc. | Human immunodeficiency virus transcription inhibitors and methods of their use |
| KR20160027968A (ko) * | 2013-06-07 | 2016-03-10 | 라나 테라퓨틱스, 인크. | Foxp3 발현을 조절하기 위한 조성물 및 방법 |
| EP3672579A4 (en) * | 2017-10-10 | 2021-06-23 | University of Virginia Patent Foundation | COMPOSITIONS AND METHODS OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND GEOGRAPHICAL ATROPHY |
| SG11202101946YA (en) * | 2018-09-18 | 2021-04-29 | I Mab Biopharma Hangzhou Co Ltd | Anti-ifnar1 antibodies for treating autoimmune diseases |
| WO2020072991A1 (en) * | 2018-10-05 | 2020-04-09 | Ionis Pharmaceuticals, Inc. | Modified oligomeric compounds and uses thereof |
| US12281305B2 (en) * | 2018-11-21 | 2025-04-22 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing prion expression |
-
2022
- 2022-06-17 EP EP22825887.7A patent/EP4355338A4/en active Pending
- 2022-06-17 JP JP2023577658A patent/JP2024523363A/ja active Pending
- 2022-06-17 WO PCT/US2022/033936 patent/WO2022266415A1/en not_active Ceased
- 2022-06-17 US US18/570,839 patent/US20250188476A1/en active Pending
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040241651A1 (en) * | 2000-04-07 | 2004-12-02 | Alexander Olek | Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations |
| US20070093437A1 (en) * | 2001-05-18 | 2007-04-26 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of xiap gene expression using short interfering nucleic acid (sina) |
| JP2010537629A (ja) * | 2007-08-30 | 2010-12-09 | アカデミシュ ジーケンハウス ビイ デ ユニヴェアズィテート ファン アムステルダム | 動脈形成に関与する経路及びその使用 |
| WO2012068630A1 (en) * | 2010-11-26 | 2012-05-31 | The University Of Melbourne | Methods and compositions comprising antagonists of type 1 interferon-mediated signalling for reducing a neuroinflammatory response in the central nervous system following a stroke |
| JP2015513912A (ja) * | 2012-04-02 | 2015-05-18 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | タンパク質の産生のための修飾ポリヌクレオチド |
| WO2016009430A1 (en) * | 2014-07-14 | 2016-01-21 | Yeda Research And Development Co. Ltd | Reduction of aging-induced type i interferon signaling at the brain's choroid plexus or within the cns for treatment of disease or injury of the cns |
| CN104312973A (zh) * | 2014-10-09 | 2015-01-28 | 北京师范大学 | I型干扰素在诱导atx蛋白表达中的应用 |
| JP2018511307A (ja) * | 2015-04-03 | 2018-04-26 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | Tmprss6発現を調節するための化合物及び方法 |
| JP2019506438A (ja) * | 2016-02-24 | 2019-03-07 | チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド | がんの処置のためのsmc組合せ療法 |
| JP2020517296A (ja) * | 2017-04-28 | 2020-06-18 | アベリノ ラボ ユーエスエー インコーポレイテッドAvellino Lab USA, Inc. | 円錐角膜に関連する対立遺伝子を検出する方法 |
| JP2021512629A (ja) * | 2018-02-12 | 2021-05-20 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | 修飾化合物及びその使用 |
| WO2020205463A1 (en) * | 2019-03-29 | 2020-10-08 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating ube3a-ats |
| WO2021087164A1 (en) * | 2019-10-30 | 2021-05-06 | Shire Human Genetic Therapies, Inc. | Methods for detecting oligonucleotides |
Also Published As
| Publication number | Publication date |
|---|---|
| US20250188476A1 (en) | 2025-06-12 |
| EP4355338A4 (en) | 2025-12-24 |
| WO2022266415A1 (en) | 2022-12-22 |
| EP4355338A1 (en) | 2024-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7557469B2 (ja) | Appの発現を低減するための化合物及び方法 | |
| JP7780564B2 (ja) | プリオン発現を低減するための化合物及び方法 | |
| JP7550165B2 (ja) | Ube3a-atsを調節するための化合物及び方法 | |
| JP7557378B2 (ja) | Stmn2発現を増加させるための化合物及び方法 | |
| JP2025121956A (ja) | Lrrk2発現を低減するための化合物及び方法 | |
| JP2024520205A (ja) | Unc13aの発現を調節するための化合物 | |
| JP2024539596A (ja) | タウ発現を低減するための化合物及び方法 | |
| JP2024504377A (ja) | Dux4の発現を低減するための化合物及び方法 | |
| JP7696466B2 (ja) | Smn2を調節するための化合物及び方法 | |
| JP7564817B2 (ja) | kcnt1発現を低減するための化合物及び方法 | |
| JP2023536472A (ja) | Appの発現を低減するための化合物及び方法 | |
| JP2023543215A (ja) | Apoeの発現を低減するための化合物及び方法 | |
| JP2024540537A (ja) | プログラニュリン発現を調節するための化合物及び方法 | |
| JP7561129B2 (ja) | Pmp22の発現を低減するための化合物及び方法 | |
| JP2024506351A (ja) | Plnの発現を低減するための化合物及び方法 | |
| AU2022334739A1 (en) | Compounds and methods for modulating scn1a expression | |
| JP7511563B2 (ja) | Cln3の発現を調節するための化合物及び方法 | |
| US20250188476A1 (en) | Compounds and methods for reducing ifnar1 expression | |
| JP2026062868A (ja) | Plp1を調節するための化合物及び方法 | |
| JP2024505226A (ja) | ハンチンチンを調節するための化合物及び方法 | |
| JP2023530072A (ja) | Pmp22を調節するための化合物及び方法 | |
| JP7738573B2 (ja) | Atxn1を調節するための化合物及び方法 | |
| JP2026506010A (ja) | App発現を低減するための化合物及び方法 | |
| WO2024064854A2 (en) | Compounds and methods for reducing mecp2 expression | |
| JP2023544162A (ja) | Chmp7を調節するための化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250617 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250617 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260522 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260810 |